Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Sackner-Bernstein

JAMA

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
JAMA|April 12, 2017
FDA Approval of Eteplirsen for Muscular DystrophyJonathan Sackner-Bernstein
JAMA|September 11, 2003
The JNC 7 hypertension guidelinesJonathan Sackner-Bernstein
JAMA|September 28, 2006
Risk of death associated with nesiritide in patients with acutely decompensated heart failureKeith D Aaronson, Jonathan Sackner-Bernstein
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
JAMA|April 12, 2017
FDA Approval of Eteplirsen for Muscular DystrophyJonathan Sackner-Bernstein
JAMA|September 11, 2003
The JNC 7 hypertension guidelinesJonathan Sackner-Bernstein
JAMA|September 28, 2006
Risk of death associated with nesiritide in patients with acutely decompensated heart failureKeith D Aaronson, Jonathan Sackner-Bernstein
Pageof 1